SCHEMBL4283474

SCHEMBL4283474

CC(C)(C)c1cc(N2CCN(C(=O)c3cc(-c4ccccc4)nc(-c4ccccc4)c3)CC2)cc(C(C)(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 9/20 0.54
ACACA Q13085 9/20 0.54
MGLL Q99685 2/20 0.49
ABL1 P00519 1/20 0.49
BCR P11274 1/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
KMT2A Q03164 1/20 0.49
SLC6A7 Q99884 1/20 0.49
TACR3 P29371 1/20 0.47
USP2 O75604 1/20 0.47
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
TRPV1 Q8NER1 1/20 0.47
DRD2 P14416 1/20 0.47
DRD3 P35462 1/20 0.47
ABCB1 P08183 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4273078 0.85 LMNA (0.60) MEN1POLBKMT2ASLC6A7USP2
SCHEMBL23244159 0.81 LMNA (0.63) ACACBACACAMGLLMEN1POLB
SCHEMBL4276349 0.79 SMN1; SMN2 (0.58) ABL1BCRMEN1KMT2ALMNA
SCHEMBL23244255 0.76 ACACB (0.53) ACACBACACAMEN1POLBKMT2A
SCHEMBL4285352 0.76 MAPT (0.45) MEN1POLBKMT2ASLC6A7TACR3
SCHEMBL4274664 0.75 HSP90AA1 (0.59) MEN1POLBKMT2ASLC6A7LMNA
SCHEMBL4285450 0.74 TSHR (0.46) MEN1KMT2AUSP2LMNAMAPT
SCHEMBL23259361 0.73 SLC6A7 (0.60) ACACBACACAMGLLMEN1POLB
SCHEMBL23244155 0.73 ACACB (0.50) ACACBACACAMEN1POLBKMT2A
SCHEMBL29576533 0.73 ACACB (0.50) ACACBACACAMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-10-29 US disclosed
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-10-29 US disclosed
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS ZALICUS PHARMACEUTICALS LTD. (CA) 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270413-A1 DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1G, CACNA1C, CACNA1I ACACB 2753/4885ACACA 2568/4885MGLL 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.